Drug-Induced Photosensitivity 

  • Author: Alexandra Y Zhang, MD; Chief Editor: Dirk M Elston, MD   more...
 
Updated: Jan 15, 2010
 

Background

Drug-induced photosensitivity refers to the development of cutaneous disease as a result of the combined effects of a chemical and light. Exposure to either the chemical or the light alone is not sufficient to induce the disease; however, when photoactivation of the chemical occurs, one or more cutaneous manifestations may arise. These include phototoxic and photoallergic reactions, a planus lichenoides reaction, pseudoporphyria, and subacute cutaneous lupus erythematosus. Photosensitivity reactions may result from systemic medications and topically applied compounds (see Table 1 below).

Wavelengths within the UV-A (320-400 nm) range and, for certain compounds, within the visible range, are more likely to cause drug-induced photosensitivity reactions, although occasionally UV-B (290-320 nm) can also be responsible for such effects. UV-B wavelengths are most efficient at causing sunburn and nonmelanoma skin cancer. In patients who present with photosensitivity, it is often difficult to differentiate phototoxic from photoallergic reactions. However, they have a number of distinguishing characteristics (see Table 2 below).

Table 1. Common Photosensitizing Medications (Open Table in a new window)

Class Medication Phototoxic Reaction Photoallergic Reaction Lichenoid Reaction Pseudoporphyria Subacute Cutaneous Lupus Erythematosus
AntibioticsTetracyclines (doxycycline, tetracycline)YesNoYesYesNo
Fluoroquinolones (ciprofloxacin, ofloxacin, levofloxacin)[1] YesNoNoNoNo
SulfonamidesYesNoNoNoNo
Nonsteroidal anti-inflammatory drugs[2] IbuprofenYesNoYesNoNo
KetoprofenYesYesNoNoNo
Naproxen[3] YesNoYesYesNo
Celecoxib[4] NoYesNoYesNo
DiureticsFurosemideYesNoNoYesNo
BumetanideNoNoNoYesNo
HydrochlorothiazideYesNoNoNoYes
RetinoidIsotretinoinYesNoNoNoNo
AcitretinYesNoNoNoNo
HypoglycemicsSulfonylureas (glipizide, glyburide)[1] NoYesYesYesNo
HMG-CoA* reductase inhibitorsStatins (atorvastatin, fluvastatin, lovastatin, pravastatin, simvastatin)[5] YesYesYesYesNo
Epidermal growth factor receptor inhibitorsCetuximab, panitumumab, erlotinib, gefitinib, lapatinib, vandetanib[6] YesYesYesYesNo
Photodynamic therapy prophotosensitizers5-Aminolevulinic acid[7] YesNoNoNoNo
Methyl-5-aminolevulinic acidYesNoNoNoNo
Verteporfin[8] YesNoNoNoNo
Photofrin[9] YesNoNoNoNo
Neuroleptic drugs[10] Phenothiazines (chlorpromazine, fluphenazine, perazine, perphenazine, thioridazine)[11] YesYesYesNoNo
Thioxanthenes (chlorprothixene, thiothixene)YesNoNoNoNo
AntifungalsTerbinafineNoNoNoNoYes
ItraconazoleYesYesNoNoNo
Voriconazole[12, 13, 14, 15] YesNoNoYesNo
GriseofulvinYesYesNoNoYes
Other drugsPara-aminobenzoic acidYesYesNoNoNo
5-FluorouracilYesYesYesYesNo
Paclitaxel[2, 16] YesNoNoNoYes
AmiodaroneYesNoNoYesNo
DiltiazemYesNoNoNoYes
QuinidineYesYesYesNoNo
HydroxychloroquineNoNoYesNoNo
Coal tarYesNoNoNoNo
EnalaprilNoNoNoNoYes
DapsoneNoYesYesYesNo
Oral contraceptives[17, 18] NoYesNoYesNo
Sunscreens[19] Para-aminobenzoic acidNoYesNoNoNo
CinnamatesNoYesNoNoNo
BenzophenonesNoYesNoNoNo
SalicylatesNoYesNoNoNo
FragrancesMusk ambretteNoYesNoNoNo
6-MethylcoumarinNoYesNoNoNo
*3-Hydroxy-3-methylglutaryl coenzyme A.

Phototoxic reactions occur because of the damaging effects of light-activated compounds on cell membranes and, in some instances, DNA. By contrast, photoallergic reactions are cell-mediated immune responses to a light-activated compound. Phototoxic reactions develop in most individuals if they are exposed to sufficient amounts of light and drug. Typically, they appear as an exaggerated sunburn response, as shown in the image below.

Phototoxic reaction. Phototoxic reaction.

Photoallergic reactions resemble allergic contact dermatitis, with a distribution limited to sun-exposed areas of the body. However, when the reactions are severe or prolonged, they may extend into covered areas of skin.

Table 2. Distinguishing Characteristics of Phototoxic and Photoallergic Reactions (Open Table in a new window)

Feature Phototoxic Reaction Photoallergic Reaction
IncidenceHighLow
Amount of agent required for photosensitivityLargeSmall
Onset of reaction after exposure to agent and lightMinutes to hours24-72 hours
More than one exposure to agent requiredNoYes
DistributionSun-exposed skin onlySun-exposed skin, may spread to unexposed areas
Clinical characteristicsExaggerated sunburnDermatitis
Immunologically mediatedNoYes; Type IV

Photoallergic reactions develop in only a minority of individuals exposed to the compound and light; they are less prevalent than phototoxic skin reactions. The amount of drug required to elicit photoallergic reactions is considerably smaller than that required for phototoxic reactions. Moreover, photoallergic reactions, as shown in the image below, are a form of cell-mediated immunity; their onset often is delayed by as long as 24-72 hours after exposure to the drug and light. By contrast, phototoxic responses often occur within minutes or hours of light exposure.

Photoallergic reaction. Photoallergic reaction.
Next

Pathophysiology

Phototoxicity

Phototoxic reactions result from direct damage to tissue caused by a photoactivated compound. Many compounds have the potential to cause phototoxicity. Most have at least one resonating double bond or an aromatic ring that can absorb radiant energy. Most compounds are activated by wavelengths within the UV-A (320-400 nm) range, although some compounds have a peak absorption within the UV-B or visible range.

In most instances, photoactivation of a compound results in the excitation of electrons from the stable singlet state to an excited triplet state. As excited-state electrons return to a more stable configuration, they transfer their energy to oxygen, leading to the formation of reactive oxygen intermediates. Reactive oxygen intermediates such as an oxygen singlet, superoxide anion, and hydrogen peroxide damage cell membranes and DNA. Signal transduction pathways that lead to the production of proinflammatory cytokines and arachidonic acid metabolites are also activated. The result is an inflammatory response that has the clinical appearance of an exaggerated sunburn reaction.

The exception to this mechanism of drug-induced phototoxicity is psoralen-induced phototoxicity. Psoralens intercalate within DNA, forming monofunctional adducts. Exposure to UV-A radiation produces bifunctional adducts within DNA. Exactly how bifunctional adducts cause photosensitivity is unknown.

Photoallergic reactions

Photoallergic reactions are cell-mediated immune responses in which the antigen is a light-activated drug. Photoactivation results in the development of a metabolite that can bind to protein carriers in the skin to form a complete antigen. The reaction then proceeds exactly as other cell-mediated immune responses do. Specifically, Langerhans cells and other antigen-presenting cells take up the antigen and then migrate to regional lymph nodes. In those locations, the Langerhans cells present the photoallergen to T lymphocytes that express antigen-specific receptors. The T cells become activated and proliferate, and they return to the site of photoallergen deposition. In the skin, the T cells orchestrate an inflammatory response that usually has an eczematous morphology if the photoallergen is applied topically or the characteristics of a drug eruption if the photoallergen is administered systemically.

Previous
Next

Epidemiology

Frequency

United States

Although the incidence of drug-induced photosensitivity in the United States is uncertain. Phototoxic reactions are considerably more common than photoallergic reactions.

International

The incidence of drug-induced photosensitivity is unknown.

Mortality/Morbidity

Drug-induced photosensitivity is associated with death only in rare individuals who are exposed to large amounts of sunlight after taking large doses of psoralens. Although mortality is rare, drug-induced photosensitivity can cause significant morbidity in some individuals, who must severely limit their exposure to natural or artificial light. The carcinogenic potential due to prolonged exposure to these photosensitizing drugs has been suggested; its clinical relevance remains to be determined.

Race

The racial incidence of drug-induced photosensitivity reactions is unknown. Photosensitivity reactions can occur in races with heavily pigmented skin.

Sex

Men are more likely to have photoallergic reactions than women.

Age

Drug-induced photosensitivity reactions can occur in persons of any age.

Previous
 
 
Contributor Information and Disclosures
Author

Alexandra Y Zhang, MD  Assistant Professor, Department of Dermatology, University of Pittsburgh

Alexandra Y Zhang, MD is a member of the following medical societies: American Academy of Dermatology, Dermatology Foundation, and Women's Dermatologic Society

Disclosure: Nothing to disclose.

Coauthor(s)

Craig A Elmets, MD  Professor and Chair, Department of Dermatology, Director, UAB Skin Diseases Research Center, University of Alabama at Birmingham School of Medicine

Craig A Elmets, MD is a member of the following medical societies: American Academy of Dermatology, American Association of Immunologists, American College of Physicians, American Federation for Medical Research, and Society for Investigative Dermatology

Disclosure: Palomar Medical Technologies Stock None; Astellas Consulting fee Review panel membership; Massachusetts Medical Society Salary Employment; Abbott Laboratories Grant/research funds Independent contractor; UpToDate Salary Employment; Biogen Grant/research funds Independent contractor; Clinuvel Independent contractor; Covan Basilea Pharmaceutical Grant/research funds Independent contractor; ISDIN None Consulting; TenX BIopharma Grant/research funds Independent contractor

Specialty Editor Board

Abdul-Ghani Kibbi, MD  Professor and Chair, Department of Dermatology, American University of Beirut Medical Center, Lebanon

Disclosure: none None None

David F Butler, MD  Professor of Dermatology, Texas A&M University College of Medicine; Chair, Department of Dermatology, Director, Dermatology Residency Training Program, Scott and White Clinic, Northside Clinic

David F Butler, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, American Society for Dermatologic Surgery, American Society for MOHS Surgery, Association of Military Dermatologists, and Phi Beta Kappa

Disclosure: Nothing to disclose.

Jeffrey P Callen, MD  Professor of Medicine (Dermatology), Chief, Division of Dermatology, University of Louisville School of Medicine

Jeffrey P Callen, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Physicians, and American College of Rheumatology

Disclosure: Amgen Honoraria Consulting; Abbott Honoraria Consulting; Electrical Optical Sciences Consulting fee Consulting; Celgene Honoraria Safety Monitoring Committee; GSK - Glaxo Smith Kline Consulting fee Consulting; TenXBioPharma Consulting fee Safety Monitoring Committee

Catherine M Quirk, MD  Clinical Assistant Professor, Department of Dermatology, University of Pennsylvania

Catherine M Quirk, MD is a member of the following medical societies: Alpha Omega Alpha and American Academy of Dermatology

Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD  Director, Department of Dermatology, Geisinger Medical Center

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

References
  1. Fox GN, Harrell CC, Mehregan DR. Extensive lichenoid drug eruption due to glyburide: a case report and review of the literature. Cutis. Jul 2005;76(1):41-5. [Medline].

  2. Onoue S, Seto Y, Gandy G, Yamada S. Drug-induced phototoxicity; an early in vitro identification of phototoxic potential of new drug entities in drug discovery and development. Curr Drug Saf. May 2009;4(2):123-36. [Medline].

  3. Günes AT, Fetil E, Ilknur T, Birgin B, Ozkan S. Naproxen-induced lichen planus: report of 55 cases. Int J Dermatol. Jun 2006;45(6):709-12. [Medline].

  4. Yazici AC, Baz K, Ikizoglu G, Kokturk A, Uzumlu H, Tataroglu C. Celecoxib-induced photoallergic drug eruption. Int J Dermatol. Jun 2004;43(6):459-61. [Medline].

  5. Suchak R, Benson K, Swale V. Statin-induced Ro/SSa-positive subacute cutaneous lupus erythematosus. Clin Exp Dermatol. Sep 2007;32(5):589-91. [Medline].

  6. Kong HH, Fine HA, Stern JB, Turner ML. Cutaneous pigmentation after photosensitivity induced by vandetanib therapy. Arch Dermatol. Aug 2009;145(8):923-5. [Medline].

  7. Gupta AK, Ryder JE. Photodynamic therapy and topical aminolevulinic acid: an overview. Am J Clin Dermatol. 2003;4(10):699-708. [Medline].

  8. Houle JM, Strong HA. Duration of skin photosensitivity and incidence of photosensitivity reactions after administration of verteporfin. Retina. Dec 2002;22(6):691-7. [Medline].

  9. Moriwaki SI, Misawa J, Yoshinari Y, Yamada I, Takigawa M, Tokura Y. Analysis of photosensitivity in Japanese cancer-bearing patients receiving photodynamic therapy with porfimer sodium (Photofrin). Photodermatol Photoimmunol Photomed. Oct 2001;17(5):241-3. [Medline].

  10. Eberlein-Konig B, Bindl A, Przybilla B. Phototoxic properties of neuroleptic drugs. Dermatology. 1997;194(2):131-5. [Medline].

  11. Llambrich A, Lecha M. Photoinduced lichenoid reaction by thioridazine. Photodermatol Photoimmunol Photomed. Apr 2004;20(2):108-9. [Medline].

  12. Dolan CK, Hall MA, Blazes DL, Norwood CW. Pseudoporphyria as a result of voriconazole use: a case report. Int J Dermatol. Oct 2004;43(10):768-71. [Medline].

  13. Patel AR, Turner ML, Baird K, et al. Voriconazole-induced phototoxicity masquerading as chronic graft-versus-host disease of the skin in allogeneic hematopoietic cell transplant recipients. Biol Blood Marrow Transplant. Mar 2009;15(3):370-6. [Medline].

  14. Racette AJ, Roenigk HH Jr, Hansen R, Mendelson D, Park A. Photoaging and phototoxicity from long-term voriconazole treatment in a 15-year-old girl. J Am Acad Dermatol. May 2005;52(5 Suppl 1):S81-5. [Medline].

  15. Rubenstein M, Levy ML, Metry D. Voriconazole-induced retinoid-like photosensitivity in children. Pediatr Dermatol. Nov-Dec 2004;21(6):675-8. [Medline].

  16. Cohen PR. Photodistributed erythema multiforme: paclitaxel-related, photosensitive conditions in patients with cancer. J Drugs Dermatol. Jan 2009;8(1):61-4. [Medline].

  17. Morison WL. Solar urticaria due to progesterone compounds in oral contraceptives. Photodermatol Photoimmunol Photomed. Jun 2003;19(3):155-6. [Medline].

  18. Silver EA, Silver AH, Silver DS, McCalmont TH. Pseudoporphyria induced by oral contraceptive pills. Arch Dermatol. Feb 2003;139(2):227-8. [Medline].

  19. Gonzalez E, Gonzalez S. Drug photosensitivity, idiopathic photodermatoses, and sunscreens. J Am Acad Dermatol. Dec 1996;35(6):871-85; quiz 886-7. [Medline].

  20. Ellgehausen P, Elsner P, Burg G. Drug-induced lichen planus. Clin Dermatol. May-Jun 1998;16(3):325-32. [Medline].

  21. Reed BR, Huff JC, Jones SK, Orton PW, Lee LA, Norris DA. Subacute cutaneous lupus erythematosus associated with hydrochlorothiazide therapy. Ann Intern Med. Jul 1985;103(1):49-51. [Medline].

  22. Callen JP, Hughes AP, Kulp-Shorten C. Subacute cutaneous lupus erythematosus induced or exacerbated by terbinafine: a report of 5 cases. Arch Dermatol. Sep 2001;137(9):1196-8. [Medline].

  23. Allen JE. Drug-induced photosensitivity. Clin Pharm. Aug 1993;12(8):580-7. [Medline].

  24. Gould JW, Mercurio MG, Elmets CA. Cutaneous photosensitivity diseases induced by exogenous agents. J Am Acad Dermatol. Oct 1995;33(4):551-73; quiz 574-6. [Medline].

  25. Hrabovsky SL, Elmets CA. Pathogenesis, characteristics, diagnosis, and treatment of pseudoporphyria. Curr Opin in Dermatol. 1996;3:105-10.

Previous
Next
 
Phototoxic reaction.
Photoallergic reaction.
Pseudoporphyria.
Subacute cutaneous lupus erythematosus exacerbated by terbinafine. Courtesy of Jeffrey P. Callen.
Table 1. Common Photosensitizing Medications
Class Medication Phototoxic Reaction Photoallergic Reaction Lichenoid Reaction Pseudoporphyria Subacute Cutaneous Lupus Erythematosus
AntibioticsTetracyclines (doxycycline, tetracycline)YesNoYesYesNo
Fluoroquinolones (ciprofloxacin, ofloxacin, levofloxacin)[1] YesNoNoNoNo
SulfonamidesYesNoNoNoNo
Nonsteroidal anti-inflammatory drugs[2] IbuprofenYesNoYesNoNo
KetoprofenYesYesNoNoNo
Naproxen[3] YesNoYesYesNo
Celecoxib[4] NoYesNoYesNo
DiureticsFurosemideYesNoNoYesNo
BumetanideNoNoNoYesNo
HydrochlorothiazideYesNoNoNoYes
RetinoidIsotretinoinYesNoNoNoNo
AcitretinYesNoNoNoNo
HypoglycemicsSulfonylureas (glipizide, glyburide)[1] NoYesYesYesNo
HMG-CoA* reductase inhibitorsStatins (atorvastatin, fluvastatin, lovastatin, pravastatin, simvastatin)[5] YesYesYesYesNo
Epidermal growth factor receptor inhibitorsCetuximab, panitumumab, erlotinib, gefitinib, lapatinib, vandetanib[6] YesYesYesYesNo
Photodynamic therapy prophotosensitizers5-Aminolevulinic acid[7] YesNoNoNoNo
Methyl-5-aminolevulinic acidYesNoNoNoNo
Verteporfin[8] YesNoNoNoNo
Photofrin[9] YesNoNoNoNo
Neuroleptic drugs[10] Phenothiazines (chlorpromazine, fluphenazine, perazine, perphenazine, thioridazine)[11] YesYesYesNoNo
Thioxanthenes (chlorprothixene, thiothixene)YesNoNoNoNo
AntifungalsTerbinafineNoNoNoNoYes
ItraconazoleYesYesNoNoNo
Voriconazole[12, 13, 14, 15] YesNoNoYesNo
GriseofulvinYesYesNoNoYes
Other drugsPara-aminobenzoic acidYesYesNoNoNo
5-FluorouracilYesYesYesYesNo
Paclitaxel[2, 16] YesNoNoNoYes
AmiodaroneYesNoNoYesNo
DiltiazemYesNoNoNoYes
QuinidineYesYesYesNoNo
HydroxychloroquineNoNoYesNoNo
Coal tarYesNoNoNoNo
EnalaprilNoNoNoNoYes
DapsoneNoYesYesYesNo
Oral contraceptives[17, 18] NoYesNoYesNo
Sunscreens[19] Para-aminobenzoic acidNoYesNoNoNo
CinnamatesNoYesNoNoNo
BenzophenonesNoYesNoNoNo
SalicylatesNoYesNoNoNo
FragrancesMusk ambretteNoYesNoNoNo
6-MethylcoumarinNoYesNoNoNo
*3-Hydroxy-3-methylglutaryl coenzyme A.
Table 2. Distinguishing Characteristics of Phototoxic and Photoallergic Reactions
Feature Phototoxic Reaction Photoallergic Reaction
IncidenceHighLow
Amount of agent required for photosensitivityLargeSmall
Onset of reaction after exposure to agent and lightMinutes to hours24-72 hours
More than one exposure to agent requiredNoYes
DistributionSun-exposed skin onlySun-exposed skin, may spread to unexposed areas
Clinical characteristicsExaggerated sunburnDermatitis
Immunologically mediatedNoYes; Type IV
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.